01—Abstract
Summary
Summary of the 8-K filed April 22, 2024. Cited figures are marked; the original filing is the authoritative source.
Cardinal Health (NYSE: CAH) disclosed in an April 22, 2024 news release that its pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, will not be renewed.
OptumRx accounted for 16% of consolidated fiscal 2023 revenue, with roughly 90% of those sales serviced by the Pharmaceutical Distribution business, mainly non-specialty bulk shipments to Optum's mail dispensing facilities. Management notes these sales carry a meaningfully lower operating margin than the Pharmaceutical and Specialty Solutions segment overall, so the revenue loss is larger than the profit loss on a proportional basis. Despite the nonrenewal, Cardinal reaffirmed its fiscal 2024 non-GAAP diluted EPS guidance of $7.20 to $7.35a and its long-term targets: 4% to 6% segment profit CAGR for Pharmaceutical and Specialty Solutions, and 12% to 14% consolidated non-GAAP EPS CAGR, both for fiscal 2024 to 2026 against a fiscal 2023 baseline.
The company has not yet issued fiscal 2025 guidance but expects growth in both segment profit and non-GAAP EPS in fiscal 2025, partly offset through new customer wins, specialty growth and other actions. Cash flow is the main near-term pressure point.
Cardinal continues to expect average adjusted free cash flow of about $2 billionb over fiscal 2024 to 2026, but expects fiscal 2025 to be lower than average due to the unwinding of negative net working capital tied to the OptumRx contract and day-of-the-week timing. Investors should watch the upcoming earnings call for the company's detailed fiscal 2025 outlook and quantification of the OptumRx impact.
02—Key points
Key Highlights
- OptumRx contracts with the Pharmaceutical Distribution business expire at the end of June 2024 and will not be renewed.
- OptumRx represented 16% of consolidated fiscal 2023 revenue; about 90% of those sales were serviced by Pharmaceutical Distribution, primarily non-specialty bulk shipments.
- OptumRx sales carry a meaningfully lower operating margin than the overall Pharmaceutical and Specialty Solutions segment.
- Fiscal 2024 non-GAAP diluted EPS guidance of $7.20 to $7.35 was reaffirmed.
- Long-term targets reaffirmed: 4% to 6% segment profit CAGR (Pharmaceutical and Specialty Solutions) and 12% to 14% consolidated non-GAAP EPS CAGR for fiscal 2024 to 2026.
- Management expects fiscal 2025 growth in segment profit and non-GAAP diluted EPS, partly offset by new customer wins, specialty growth and other actions; no formal fiscal 2025 guidance yet.
- Adjusted free cash flow expected to average about $2 billion over fiscal 2024 to 2026, but fiscal 2025 is expected to be lower due to unwinding negative working capital tied to OptumRx and day-of-week timing.
03—Questions
Frequently Asked Questions
How large is the OptumRx business relative to Cardinal Health?
OptumRx generated 16% of Cardinal Health's consolidated revenue in fiscal 2023. About 90% of those sales were handled by the Pharmaceutical Distribution business, mainly non-specialty bulk shipments to Optum's mail dispensing facilities.
Does the nonrenewal change Cardinal Health's earnings outlook?
Cardinal reaffirmed its fiscal 2024 non-GAAP diluted EPS guidance of $7.20 to $7.35 and its fiscal 2024 to 2026 long-term targets. For fiscal 2025, it has not issued formal guidance but expects growth in segment profit and non-GAAP EPS, partly offset by new customer wins, specialty growth and other actions.
Why is the impact on profit smaller than the impact on revenue?
Management said sales to OptumRx generate a meaningfully lower operating margin than the overall Pharmaceutical and Specialty Solutions segment. Losing lower-margin volume therefore reduces revenue more than it reduces segment profit.
What does this mean for free cash flow?
Cardinal still expects average adjusted free cash flow of about $2 billion from fiscal 2024 to 2026. Fiscal 2025 is expected to come in below that average because of the unwinding of negative net working capital associated with the OptumRx contract and day-of-the-week timing.
What should investors watch next?
The upcoming earnings call, where management said it will provide updates on progress. Key items include the formal fiscal 2025 outlook, how much of the OptumRx revenue and profit is replaced by new customer wins and specialty growth, and the size of the fiscal 2025 cash flow impact.
04—Continue